Navigation Links
Common anti-inflammatory coaxes liver cancer cells to commit suicide
Date:5/16/2011

s.

After designing a template molecule that would most effectively bind to STAT3, he compared that template to the 1,400 federally approved drugs already on the market.

"Celecoxib is almost identical to the molecule template. It attaches to STAT3 in three places. We can optimize celecoxib, and that is expected to come soon. But applying our technique to find those pieces and determining that they come from an existing drug makes the discovery process much faster," said Li, a key co-author of the paper and frequent research collaborator with Lin.

Li has termed this approach as in silico (computer-driven) drug repositioning or repurposing.

The discovery that celecoxib can bind to STAT3 also appears to apply to other cancers. Both Lin and Li were key authors on a recent paper that suggested that celecoxib's ability to block STAT3's function might also make it effective as a treatment for rhabdomyosarcoma, the most common soft tissue cancer in children and adolescents. This research was published in the April 15 issue of the journal Biochemical and Biophysical Research Communications.


'/>"/>

Contact: Jiayuh Lin
lin.674@osu.edu
614-722-5086
Ohio State University
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Mental Decline Common in Women Over 85: Study
2. New model taps tiny, common tropical fish for large-scale drug screening to combat Cushing disease
3. Post-traumatic stress disorder common following significant orthopedic trauma
4. DNA from common stomach bacteria minimizes effects of colitis, U-M study says
5. TVs Common in Daycare Centers, Flouting Guidelines
6. Common Painkillers May Blunt Antidepressants
7. Prenatal exposure to common insecticide linked to decreases in cognitive functioning at age 7
8. Depression Common After Brain Injury
9. Treatment-resistant epilepsy common in idiopathic autism
10. Can Common Virus, Lack of Sunlight Boost MS Risk?
11. Hookah Use Common Among College Students, Survey Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Dignity Health named Dr. ... General Hospital Emergency Room – Gilbert, opening in August. The new facility is ... in the West Valley. , “Dr. Baldwin is an excellent leader and will ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... leading provider of medical information, risk management and investigative services, has introduced ... direction toward focused, expert information solutions that improve business outcomes for its ...
(Date:8/2/2015)... ... 03, 2015 , ... A new Phase I research study is looking at ... led by Kenneth G. Lucas, M.D. , chief of the division of pediatric ... at Kosair Children’s Hospital and in the UofL Department of Pediatrics ...
(Date:8/1/2015)... ... ... Back packs can be dangerous? Whaaat?! , Not the danger that guns ... a kid's spine. With school starting again, most kids will be asking for new ... aware of how to help them prevent injuries by understanding backpack safety. , "Carrying ...
(Date:8/1/2015)... , ... August 01, 2015 , ... Tina Wilcoxson, owner ... , Wilcoxson was given that honor by the National Retail Federation, the largest retail ... Wilcoxson was one of three Maine business owners to be named as such. According ...
Breaking Medicine News(10 mins):Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Local Retail Advocate Wins National Recognition 2
... is an essential element of care for children requiring ... combining ketamine and propofol, two common medications used in ... it was unclear whether this practice was superior to ... Research led by Drs. Amit Shah, Gregory Mosdossy ...
... prostate cancer should be especially diligent about having routine ... at the University at Buffalo indicate. , Their findings ... more abnormal colon polyps, known as adenomas, and advanced ... of the research were presented Oct. 19 at a ...
... October 18, 2010 Neuralstem, Inc. (NYSE Amex: ... human clinical trial of the company,s spinal cord stem ... or Lou Gehrig,s disease) at Emory University in Atlanta, ... data from the first six non-ambulatory patients, the trial,s ...
... HealthDay Reporter , MONDAY, Oct. 18 (HealthDay ... victim to stunning medical mistakes, ranging from an operation ... for another patient, a new study finds. To ... Joint Commission in 2004 introduced a universal protocol for ...
... Mozes HealthDay Reporter , MONDAY, Oct. 18 (HealthDay ... may raise the risk for heart attack and stroke, researchers ... short-term, the study team noted. "I don,t want to ... cardiovascular risk in the period just after dental work was ...
... likely to buy unhealthy foods when they pay using ... in the Journal of Consumer Research . ... authors Manoj Thomas (Cornell University), Kalpesh Kaushik Desai (State ... University of New York, Buffalo). "First, there is a ...
Cached Medicine News:Health News:Study reveals superior sedation method for children 2Health News:Prostate cancer patients are at increased risk of precancerous colon polyps 2Health News:Neuralstem updates ALS clinical trial progress 2Health News:Surgery on Wrong Patients, Surgical Sites Persists, Study Finds 2Health News:Surgery on Wrong Patients, Surgical Sites Persists, Study Finds 3Health News:Surgery on Wrong Patients, Surgical Sites Persists, Study Finds 4Health News:Invasive Dentistry May Raise Short-Term Heart, Stroke Risk 2Health News:Invasive Dentistry May Raise Short-Term Heart, Stroke Risk 3Health News:Cash is healthier? Credit and debit increase impulsive food purchases 2
(Date:7/30/2015)... N.J. , July 30, 2015  Unichem Pharmaceuticals ... recalling one lot of Hydrochlorothiazide tablets 25 mg 1000-count ... initiated as a precautionary measure due to the identification ... the product. The risk associated with ... tablet is the increased probability of experiencing Clopidogrel,s side ...
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) ... of 2015. Key results include: , Total ... of 2014 to $5,370 million, with 6 percent ... (etanercept), Prolia ® (denosumab), Sensipar ® ... ® (denosumab). Unfavorable changes in foreign exchange ...
(Date:7/30/2015)... THOUSAND OAKS, Calif. , July 30, 2015  Amgen ... Fred Hassan , partner and managing director of Warburg Pincus ... "We are pleased to welcome Fred Hassan and ... to the Amgen Board," said Robert A. Bradway , ... expertise and commitment to innovation will serve Amgen well." ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3
... Isolation Kit (patent pending) is designed for ... / or Newcastle Disease (ND) viral RNA ... samples. This kit id validated by the ... their testing protocol for real-time RT-PCR detection ...
... This revolutionary product will provide ... any type of electroretinogram, visual evoked ... LED ganzfeld will allow you to ... including on-off, double flash, photopic negative ...
... LABOTECH is an automated microplate ... immunoenzymatic microplate techniques. Open architecture ... to many manufacturers' microplate assays ... traditional R.I.A. and I.F.A. methods ...
The Rapidpoint 400/405 instrument is a point-of-care blood gas analyzer that's fast, easy to operate and reliable....
Medicine Products: